NCT06891365View on ClinicalTrials.gov

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

January 25, 2027

Study Completion Date

January 25, 2027

Conditions
Healthy VolunteersHepatic Steatosis
Interventions
DRUG

NNC0581-0001

NNC0581-0001 will be administered subcutaneously.

DRUG

Placebo (NNC0581-0001)

Placebo matched to NNC0581-0001 will be administered subcutaneously.

Trial Locations (1)

HA1 3UJ

RECRUITING

Parexel CPRU, Level 7, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY